Fibrin Sealants Market Size

Global Fibrin Sealants Market size was valued at USD 592.9 Million in 2023 poised to grow from USD 639.1 Million in 2024 to USD 1165.6 Million by 2032, growing at a CAGR of 7.8% in the forecast period (2025-2032).

The continuous rise in the number of surgical procedures worldwide is a significant driver of the global fibrin sealants market. This growth is primarily attributed to the aging global population, which is more susceptible to chronic illnesses requiring surgical intervention, such as cardiovascular diseases, orthopedic disorders, and cancer. With more frequent and complicated surgeries, the need for effective hemostatic agents increases. The choice goes to fibrin sealants for their efficacy in rapid generation of stable clots and facilitating tissue sealing, thereby reducing blood loss, operating time, and recovery period. Increasing clinical dependence is the direct impetus for increased market demand for such biological adhesives.

One of the key trend driving the global fibrin sealants sector is the advancement of biologic and recombinant DNA technologies. These innovations have led to the development of safer, more effective fibrin sealants with longer shelf lives and reduced immunogenic risks. Improved manufacturing techniques now allow for the creation of synthetic and pathogen-free sealants, minimizing the risk of disease transmission associated with human plasma-derived products. Additionally, new formulations with enhanced adhesion and faster polymerization times provide better surgical outcomes. As a result, these cutting-edge developments are expanding the clinical acceptance and application range of fibrin sealants in modern surgical practices.

How is AI Enhancing Surgical Planning and Intraoperative Precision in the Use of Fibrin Sealants?

Artificial intelligence (AI) is playing a growing role in the global fibrin sealants market, mainly through improvement in surgical planning and post-op care. Imaging technologies based on AI, such as convolutional neural networks, improve the accuracy of fibrin sealant deployment by determining optimal sites of tissue adhesion and minimizing intraoperative bleeding and bettering surgical results. After surgery, AI-based wound monitoring platforms such as Deepwound use smartphone photographs to identify complications like infection or fibrinous exudate and allow for interventions at the appropriate time, and also for more rapid healing. Additionally, AI facilitates research and development of next-generation fibrin sealants through analysis of massive datasets to reveal patterns and predict product performance, driving innovation and market expansion.

In August 2023, Grifols, an international healthcare company, announced that it will partner with Google Cloud to tap into artificial intelligence (AI) for speeding up therapeutic development. The partnership will use large-scale language models driven by AI to improve the drug development process, which could influence the fibrin sealants market by optimizing research and development.